Search Results for "Immunotherapy"

The Fundamentals of Chemotherapy Immunotherapy Administration Renewal Course builds on the lessons you received in the Fundamentals of Chemotherapy Immunotherapy Administration Course to ensure that your chemotherapy and immunotherapy knowledge remains current and you’re continuing to progress as an experienced oncology RN.

The ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal Course will guide you through four strategically planned case studies to ensure that your chemotherapy and immunotherapy knowledge stays current and you’re continuing to progress as an experienced oncology RN.

This certificate course prepares and reinforces critical information for safe administration and use evidence to manage acute side effects and adverse events related to chemotherapy and immunotherapy administration. 

If you’re a nurse who is new to oncology, administering or planning to administer chemotherapy/immunotherapy, or caring for patients receiving chemotherapy this course is your first stop.

ONS member Theresa Latchford, RN, MS, AOCNS^®, BMTCN^®, clinical nurse specialist at Stanford Health Care in Palo Alto, CA, and member of the Silicon Valley ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss cytokine release syndrome and its associated immunotherapies. This episode is part of a new series about oncologic emergencies. We’ll add a link to future episodes in the show notes after the second episode next month.

Using antibiotics during treatment with immune checkpoint inhibitors may limit the therapy’s effect, according to study results published in the American Journal of Clinical Oncology.

Immune checkpoint inhibitors (ICIs) enhance immune response against foreign antigens, such as cancer, by manipulating checkpoints that have stopped the body from fighting them. In doing so, they also increase risk of the immune system attacking healthy cells and producing inflammatory side effects, resulting in immune-related adverse events (irAEs).

Immunotherapy has revolutionized cancer treatment, especially for patients with diseases considered otherwise incurable. Since May 2017, the U.S. Food and Drug Administration (FDA) has approved 27 immunotherapy combinations, including chemoimmunotherapy and regimens with targeted therapies, and researchers are reporting highly promising data from clinical trials of its combination with radiation.

Combination treatment with an oncolytic virus plus a PD-1 inhibitor shows promise in patients with nonmelanoma skin cancers, researchers reported in early study results during the 2022 Multidisciplinary Head and Neck Cancers Symposium.